ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
Single-Cell-Derived Primary Rectal Carcinoma Cell Lines Reflect Intratumor Heterogeneity Associated with Treatment Response.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma.NPJ precision oncology · 2026Article
- Multiparametric magnetic resonance imaging (MRI)-based radiomics model explained by the Shapley Additive exPlanations (SHAP) method for predicting complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicenter retrospective study.Quantitative imaging in medicine and surgery · 2024Article
- Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.Cancers · 2024Review
- Development and validation of comprehensive nomograms from the SEER database for predicting early mortality in metastatic rectal cancer patients.BMC gastroenterology · 2024Article
- Article
- Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations.Frontiers in oncology · 2023Article
- Distinct tumor microenvironment landscapes of rectal cancer for prognosis and prediction of immunotherapy response.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- In vivo growth of subclones derived from Lewis lung carcinoma is determined by the tumor microenvironment.American journal of cancer research · 2022Article
- Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.Therapeutic advances in medical oncology · 2022Review
- Determinants of renal cell carcinoma invasion and metastatic competence.Nature communications · 2021Observational
- TCF7L2 silencing results in altered gene expression patterns accompanied by local genomic reorganization.Neoplasia (New York, N.Y.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 2 countries.
Funding
Abstract
purposeThe standard treatment of patients with locally advanced rectal cancer consists of preoperative chemoradiotherapy (CRT) followed by surgery. However, the response of individual tumors to CRT is extremely diverse, presenting a clinical dilemma. This broad variability in treatment response is likely attributable to intratumor heterogeneity (ITH). EXPERIMENTAL
designWe addressed the impact of ITH on response to CRT by establishing single-cell-derived cell lines (SCDCL) from a treatment-naïve rectal cancer biopsy after xenografting.
resultsIndividual SCDCLs derived from the same tumor responded profoundly different to CRT
conclusionsOur model system of patient-derived SCDCLs provides evidence for the critical role of ITH for treatment response in patients with rectal cancer and shows that distinct genetic aberration profiles are associated with treatment response. We identified specific pathways as the molecular basis of treatment response of individual clones, which could be targeted in resistant subclones of a heterogenous tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.